<DOC>
	<DOCNO>NCT01376297</DOCNO>
	<brief_summary>NETU-10-29 clinical study assess safety netupitant palonosetron , two antiemetic drug , give oral dexamethasone . The objective study evaluate netupitant palonosetron safe administer prevent nausea vomit administration repeat cycle chemotherapy .</brief_summary>
	<brief_title>A Safety Study Oral Netupitant Palonosetron Prevention Nausea Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Signed write informed consent . Na√Øve cytotoxic chemotherapy . Previous biological hormonal therapy permit . Diagnosed malignant tumor . If schedule receive repeat consecutive course chemotherapy , single dose one follow agent administer Day 1 allow : Highly emetogenic chemotherapy : I.V . dose cisplatin , mechlorethamine , streptozocin , cyclophosphamide equal 1500 mg/m2 , carmustine , dacarbazine ; Moderately emetogenic chemotherapy : I.V . dose oxaliplatin , carboplatin , epirubicin , idarubicin , ifosfamide , irinotecan , daunorubicin , doxorubicin , cyclophosphamide I.V . ( less 1500 mg/m2 ) , cytarabine I.V . ( 1 g/m2 ) , azacidine , alemtuzumab , bendamustine , clofarabine . If schedule receive combination regimen , emetogenic agent give first Day 1 infusion must complete within 6 hour . If schedule receive chemotherapy agent minimal low emetogenic potential , give Day 1 follow emetogenic agent subsequent study day . ECOG Performance Status 0 , 1 , 2 Female patient either nonchildbearing potential childbearing potential commitment use contraceptive method throughout clinical trial Hematologic metabolic status adequate receiving moderately emetogenic regimen base laboratory criterion ( Total Neutrophils , Platelets , Bilirubin , Liver enzymes , Serum Creatinine Creatinine Clearance ) If female , lactate pregnant Current use illicit drug current evidence alcohol abuse . Scheduled receive either cyclophosphamide I.V . ( 500 1500 mg/m2 ) I.V . doxorubicin ( equal 40 mg/m2 ) cyclophosphamide I.V . ( 500 1500 mg/m2 ) I.V . epirubicin ( equal 60 mg/m2 ) . Scheduled receive moderately highly emetogenic chemotherapy Day 2 Day 5 follow Day 1 chemotherapy administration . Active infection uncontrolled disease except malignancy may pose unwarranted risk administer study drug patient . Known hypersensitivity contraindication 5HT3 receptor antagonist dexamethasone . Previously receive NK1 receptor antagonist Participation clinical trial involve oral netupitant administer combination palonosetron . Any investigational drug take within 4 week prior Day 1 cycle 1 , and/or schedule receive investigational drug study . Systemic corticosteroid therapy dose within 72 hour prior Day 1 cycle 1 . Topical inhale corticosteroid steroid dose less equal 10 mg prednisone daily equivalent permit . Nonstudy drug dexamethasone premedication patient schedule receive taxanes allow . Scheduled receive bone marrow transplantation and/or stem cell rescue therapy . Scheduled receive strong moderate inhibitor CYP3A4 intake within 1 week prior Day 1 Scheduled receive follow CYP3A4 substrate : terfenadine , cisapride , astemizole , pimozide . Scheduled receive CYP3A4 inducer intake within 4 week prior Day 1 History predisposition cardiac conduction abnormality , except incomplete right bundle branch block . History risk factor Torsade de Point ( heart failure , hypokalemia , family history Long QT Syndrome ) . Severe cardiovascular disease within 3 month prior Day 1 , include myocardial infarction , unstable angina pectoris , significant valvular pericardial disease , history ventricular tachycardia , symptomatic Congestive Heart Failure severe uncontrolled arterial hypertension . Any illness condition , opinion investigator , may confound result study pose unwarranted risk administer investigational product patient . Concurrent medical condition would preclude administration dexamethasone 4 day systemic fungal infection uncontrolled diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>